| Place of Origin: | China |
|---|---|
| Brand Name: | Senwayer Brand |
| Certification: | ISO, 9001, USP |
| Model Number: | 1009119-64-5 |
| Minimum Order Quantity: | 10grams |
| Price: | Discount is possible if your order is big enough |
| Packaging Details: | 10g, 20g, 50g , 100g, 500g. 1kg, 10kg |
| Delivery Time: | within 2 working days |
| Payment Terms: | T/T in advance, Money Gram, Western Union, Bank Transfer. |
| Supply Ability: | 1000kg/month |
| CAS: | 1009119-64-5 | Apparence: | White Powder |
|---|---|---|---|
| Purity: | 99% | Other Name: | BMS-790052; EBP 883; Daclatasvir; |
| Grade: | Pharma Grade | Usage: | Treat A Certain Type Of Chronic Hepatitis C |
| High Light: | pharmaceutical raw chemical,api raw material |
||
Daclatasvir BMS-790052 Hepatitis C Treatment Drugs CAS 1009119-64-5 White Powder
Quick detail
| Daclatasvir | |
| CAS No.: | 1009119-64-5 |
| Synonyms: |
Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester; |
| Formula: | C40H50N8O6 |
| Exact Mass: | 738.38500 |
| Molecular Weight: | 738.87500 |
| PSA: | 174.64000 |
| LogP: | 6.87960 |
Daclatasvir Description
Daclatasvir is used along with another medication (sofosbuvir [Solvadi]) to treat a certain type of chronic hepatitis C (an ongoing viral infection that damages the liver). Daclatasvir is in a class of antiviral medications called hepatitis C virus (HCV) NS5A inhibitors. It works by stopping the virus that causes hepatitis C from spreading inside the body. It is not known if daclatasvir prevents the spread of hepatitis C to other people.
Daclatasvir Uses
| Uses 1 |
Treatment for the ALLY-3 Clinical Trial |
| Uses 2 | Treatment for Hepatitis C Genotype 3 |
| Uses 3 | Treatment for Bristol-Myers Squibb’s Patient Support Connect Program |
| Uses 4 |
Treatment for Bristol-Myers Squibb in HCV
|
Who can use daclatasvir
Daclatasvir is indicated for use by adults with chronic hepatitis C, meaning infection lasting more than six months. It is approved for people with HCV genotype 1, 2, 3 or 4. Genotype 1 is the most common type in Europe and considered the hardest to treat.
Daclatasvir can be used by people being treated for hepatitis C for the first time (known as 'treatment-naive') and for retreatment of people who were not cured with previous interferon-based therapy (known as 'treatment-experienced').
The safety and effectiveness of daclatasvir for people with HIV and HCV co-infection has not yet been determined, but this is now being tested. Studies have shown that daclatasvir does not have problematic interactions with most widely used HIV drugs. People with HIV and HCV co-infection who want to take daclatasvir should do so under the care of a doctor who has experience treating both HIV and HCV.
Daclatasvir can be used by people with all stages of compensated liver disease including cirrhosis. However, it works better for people with less advanced liver damage. Daclatasvir is now being tested for people with chronic hepatitis C who are awaiting or have received liver transplants.
How is daclatasvir taken
Daclatasvir is available in 30 and 60mg tablets, and the usual dose is 60mg once daily with or without food. It must be used in combination with other hepatitis C medications and is not effective if taken alone. Treatment should be managed by a doctor who has experience treating hepatitis C.
|
|
|
|
|
Genotype 1 |
Daclatasvir & sofosbuvir |
12 weeks (no cirrhosis) |
|
Genotype 1 |
Daclatasvir & sofosbuvir & ribavirin |
12 weeks (post-liver transplant, no cirrhosis) |
|
Genotype 2 |
Daclatasvir & sofosbuvir | Evidence lacking to make a recommendation on duration; at least 12 weeks. |
|
Genotype 3 |
Daclatasvir & sofosbuvir | 12 weeks (no cirrhosis) |
|
Genotype 3 |
Daclatasvir & sofosbuvir & ribavirin |
12 weeks (post-transplant, no cirrhosis) |
|
Genotype 4 |
Daclatasvir & sofosbuvir |
12 weeks (no cirrhosis) |
|
Genotype 4 |
Daclatasvir & sofosbuvir & ribavirin |
12 weeks (post-transplant or with cirrhosis A or B) |
